Antipsychotic drugs and risk of type 2 diabetes: An evidence-based approach
Article first published online: 20 SEP 2004
Copyright © 2004 John Wiley & Sons, Ltd.
Human Psychopharmacology: Clinical and Experimental
Volume 19, Issue 8, pages 549–558, December 2004
How to Cite
Bellantuono, C., Tentoni, L. and Donda, P. (2004), Antipsychotic drugs and risk of type 2 diabetes: An evidence-based approach. Hum. Psychopharmacol. Clin. Exp., 19: 549–558. doi: 10.1002/hup.628
- Issue published online: 30 NOV 2004
- Article first published online: 20 SEP 2004
- Manuscript Accepted: 4 AUG 2004
- Manuscript Received: 12 MAY 2004
- type 2 diabetes;
- antipsychotic drugs
To review studies conducted to evaluate the risk of type 2 diabetes in patients treated with different antipsychotic drugs (AP).
a MEDLINE search (January 1985–February 2003) was conducted to establish the potential relationship between the exposure to AP (conventional and second generation) and the development of type 2 diabetes. Studies were classified according to their experimental design as prospective and retrospective (incidence and prevalence based).
Twenty-one studies were selected: nine prospective and eleven retrospective.
Data Synthesis and Conclusions
Patients with schizophrenia treated with different AP have an increased risk of developing type 2 diabetes compared with the general population. The data so far available, however, do not establish whether the increasing risk of developing diabetes is a function of the schizophrenia itself or is induced by the antipsychotic treatment. A number of methodological flaws in the study design and data collection do not allow conclusions to be drawn on the risk between patients treated with conventional drugs versus those treated with new ones. Copyright © 2004 John Wiley & Sons, Ltd.